

# Sam M Hanash

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4411526/sam-m-hanash-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99  
papers

8,306  
citations

46  
h-index

91  
g-index

107  
ext. papers

10,151  
ext. citations

9.9  
avg, IF

5.62  
L-index

#	Paper	IF	Citations
99	Proteomic Profiling of the Tumor Microenvironment.. <i>Methods in Molecular Biology</i> , <b>2022</b> , 2435, 157-167	1.4	0
98	Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101460	2.2	1
97	Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma. <i>Cancers</i> , <b>2022</b> , 14, 2543	6.6	5
96	CES2 sustains HNF4 $\alpha$ expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop.. <i>Molecular Metabolism</i> , <b>2021</b> , 101426	8.8	0
95	Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. <i>Gut</i> , <b>2021</b> , 70, 2055-2065	19.2	9
94	Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 50	7.8	1
93	Protein citrullination as a source of cancer neoantigens <b>2021</b> , 9,		6
92	A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e4969-e4980	5.6	1
91	Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 228-236	8.9	5
90	Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. <i>Gastroenterology</i> , <b>2021</b> , 160, 1373-1383.e6	13.3	23
89	The length of the receiver operating characteristic curve and the two cutoff Youden index within a robust framework for discovery, evaluation, and cutoff estimation in biomarker studies involving improper receiver operating characteristic curves. <i>Statistics in Medicine</i> , <b>2021</b> , 40, 1767-1789	2.3	2
88	A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
87	SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	3
86	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. <i>Nature Medicine</i> , <b>2021</b> , 27, 141-151	50.5	30
85	Plasma-Derived Extracellular Vesicles Convey Protein Signatures that Reflect Pathophysiology in Lung and Pancreatic Adenocarcinomas. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
84	Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy. <i>Cells</i> , <b>2020</b> , 9,	7.9	15
83	Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7

82	Development of autoantibody signatures for common cancers. <i>Seminars in Immunology</i> , <b>2020</b> , 47, 101388	0.7	14
81	CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes.. <i>JCO Precision Oncology</i> , <b>2020</b> , 4, 426-436	3.6	3
80	Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 4279	17.4	27
79	Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. <i>Gut</i> , <b>2020</b> , 69, 18-31	19.2	39
78	Association Between Plasma Diacetylspermine and Tumor Spermine Synthase With Outcome in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 607-616	9.7	16
77	Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
76	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. <i>Nature</i> , <b>2019</b> , 568, 410-414	50.4	74
75	A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer. <i>Npj Precision Oncology</i> , <b>2019</b> , 3, 10	9.8	10
74	Whole Genome-Derived Tiled Peptide Arrays Detect Prediagnostic Autoantibody Signatures in Non-Small-Cell Lung Cancer. <i>Cancer Research</i> , <b>2019</b> , 79, 1549-1557	10.1	9
73	A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 372-379	9.7	52
72	Measuring human carboxylesterase 2 activity in pancreatic cancer patient-derived xenografts using a ratiometric fluorescent chemosensor. <i>Chemical Science</i> , <b>2019</b> , 10, 8428-8437	9.4	14
71	Testing the gene expression classification of the EMT spectrum. <i>Physical Biology</i> , <b>2019</b> , 16, 025002	3	22
70	Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. <i>Nature Communications</i> , <b>2019</b> , 10, 254	17.4	79
69	Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. <i>Pharmacology &amp; Therapeutics</i> , <b>2019</b> , 194, 161-184	13.9	140
68	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , <b>2018</b> , 359, 926-930	33.3	1204
67	The Wide World of Molecular Profiling for Tumor Classification. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 743-744	5.5	1
66	Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. <i>BJU International</i> , <b>2018</b> , 121, 69-76	5.6	9
65	Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. <i>JAMA Oncology</i> , <b>2018</b> , 4, e182078	13.4	55

64	JAK/STAT3-Regulated Fatty Acid Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. <i>Cell Metabolism</i> , <b>2018</b> , 27, 136-150.e5	24.6	287
63	Blood based biomarkers beyond genomics for lung cancer screening. <i>Translational Lung Cancer Research</i> , <b>2018</b> , 7, 327-335	4.4	23
62	Interconnected feedback loops among ESRP1, HAS2, and CD44 regulate epithelial-mesenchymal plasticity in cancer. <i>APL Bioengineering</i> , <b>2018</b> , 2, 031908	6.6	46
61	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. <i>Cancer Immunology Research</i> , <b>2017</b> , 5, 319-329	12.5	9
60	Epithelial/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding?. <i>Molecular Oncology</i> , <b>2017</b> , 11, 739-754	7.9	48
59	Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109, 1-9	9.7	46
58	Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	78
57	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 10202-10207	11.5	303
56	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. <i>Nature Communications</i> , <b>2017</b> , 8, 451	17.4	72
55	In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E7301-E7310	11.5	53
54	Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling. <i>Journal of the Royal Society Interface</i> , <b>2017</b> , 14,	4.1	78
53	MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. <i>Cancer Research</i> , <b>2017</b> , 77, 4414-4425	10.1	64
52	Distinguishing mechanisms underlying EMT tristability <b>2017</b> , 1, 2		47
51	Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 95466-95480	3.3	50
50	The Emerging Role of B Cells in Tumor Immunity. <i>Cancer Research</i> , <b>2016</b> , 76, 5597-5601	10.1	194
49	Lysyl Hydroxylase 2 Is Secreted by Tumor Cells and Can Modify Collagen in the Extracellular Space. <i>Journal of Biological Chemistry</i> , <b>2016</b> , 291, 25799-25808	5.4	42
48	Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E1555-64	11.5	110
47	Deciphering the complexity of the cancer proteome for diagnostic applications. <i>Expert Review of Molecular Diagnostics</i> , <b>2016</b> , 16, 399-405	3.8	4

46	Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152300	3.7	17
45	Stability of the hybrid epithelial/mesenchymal phenotype. <i>Oncotarget</i> , <b>2016</b> , 7, 27067-84	3.3	259
44	Switching Roles of TGF- $\beta$ in Cancer Development: Implications for Therapeutic Target and Biomarker Studies. <i>Journal of Clinical Medicine</i> , <b>2016</b> , 5,	5.1	20
43	An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis. <i>Cancer Research</i> , <b>2015</b> , 75, 3246-54	10.1	29
42	Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	48
41	Mass spectrometry based proteomics for absolute quantification of proteins from tumor cells. <i>Methods</i> , <b>2015</b> , 81, 34-40	4.6	11
40	MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas. <i>Cancer Prevention Research</i> , <b>2015</b> , 8, 1112-9	3.2	23
39	Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. <i>Metabolites</i> , <b>2015</b> , 5, 192-210	5.6	51
38	Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. <i>Cancer Research</i> , <b>2015</b> , 75, 1789-800	10.1	128
37	Proteomic profiling of the tumor microenvironment: recent insights and the search for biomarkers. <i>Genome Medicine</i> , <b>2014</b> , 6, 12	14.4	23
36	Proteomic signatures associated with p53 mutational status in lung adenocarcinoma. <i>Proteomics</i> , <b>2014</b> , 14, 2750-9	4.8	18
35	Autoantibody signatures involving glycolysis and spliceosome proteins precede a diagnosis of breast cancer among postmenopausal women. <i>Cancer Research</i> , <b>2013</b> , 73, 1502-13	10.1	48
34	Unleashing the power of proteomics to develop blood-based cancer markers. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 119-26	5.5	39
33	Circulating pro-surfactant protein B as a risk biomarker for lung cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2013</b> , 22, 1756-61	4	17
32	Pro-surfactant protein B as a biomarker for lung cancer prediction. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4536-43	2.2	50
31	Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. <i>Cancer Prevention Research</i> , <b>2012</b> , 5, 1036-43	3.2	52
30	Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 1935-42	10.1	23
29	Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 142-50	19.4	230

28	Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. <i>Cancer Cell</i> , <b>2011</b> , 20, 289-99	24.3	138
27	Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. <i>Cancer Research</i> , <b>2011</b> , 71, 7670-82	10.1	113
26	Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. <i>PLoS ONE</i> , <b>2009</b> , 4, e7916	3.7	48
25	In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. <i>Cancer Research</i> , <b>2009</b> , 69, 728-30	10.1	48
24	Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. <i>Genome Medicine</i> , <b>2009</b> , 1, 47	14.4	34
23	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , <b>2008</b> , 14, 822-7	50.5	835
22	Increased throughput and reduced carryover of mass spectrometry-based proteomics using a high-efficiency nonsplit nanoflow parallel dual-column capillary HPLC system. <i>Journal of Proteome Research</i> , <b>2008</b> , 7, 2743-55	5.6	13
21	Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. <i>Molecular and Cellular Proteomics</i> , <b>2008</b> , 7, 268-81	7.6	50
20	Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5060-6	2.2	159
19	Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. <i>Cancer Research</i> , <b>2007</b> , 67, 12000-6	10.1	72
18	Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. <i>Journal of Proteome Research</i> , <b>2006</b> , 5, 112-21	5.6	183
17	Identification of a Specific Vimentin isoform that Induces an Antibody Response in Pancreatic Cancer. <i>Biomarker Insights</i> , <b>2006</b> , 1, 117727190600100	3.5	18
16	Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer. <i>Biomarker Insights</i> , <b>2006</b> , 1, 175-183	3.5	17
15	Identification of defensin alpha6 as a potential biomarker in colon adenocarcinoma. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 8260-5	5.4	37
14	Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. <i>Disease Markers</i> , <b>2004</b> , 20, 149-53	3.2	45
13	An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. <i>Cancer Research</i> , <b>2004</b> , 64, 5504-10	10.1	105
12	Integrated global profiling of cancer. <i>Nature Reviews Cancer</i> , <b>2004</b> , 4, 638-44	31.3	116
11	Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. <i>Journal of Proteome Research</i> , <b>2004</b> , 3, 261-7	5.6	116

10	Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. <i>Proteomics</i> , <b>2003</b> , 3, 2108-15	4.8	116
9	Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. <i>Proteomics</i> , <b>2003</b> , 3, 2200-7	4.8	77
8	Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. <i>American Journal of Pathology</i> , <b>2003</b> , 163, 1985-95	5.8	50
7	Protein profiles associated with survival in lung adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 13537-42	11.5	221
6	Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , <b>2002</b> , 7, 407-13	2.4	33
5	Discordant protein and mRNA expression in lung adenocarcinomas. <i>Molecular and Cellular Proteomics</i> , <b>2002</b> , 1, 304-13	7.6	719
4	A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. <i>Molecular and Cellular Proteomics</i> , <b>2002</b> , 1, 197-203	7.6	130
3	Identification of tumor-associated antigens using proteomics. <i>Technology in Cancer Research and Treatment</i> , <b>2002</b> , 1, 257-62	2.7	31
2	Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. <i>American Journal of Pathology</i> , <b>2001</b> , 159, 1231-8	5.8	164
1	Distinguishing Mechanisms Underlying EMT Tristability		2